SI9520091B - Soli anti-migrenskega derivata indola - Google Patents
Soli anti-migrenskega derivata indola Download PDFInfo
- Publication number
- SI9520091B SI9520091B SI9520091A SI9520091A SI9520091B SI 9520091 B SI9520091 B SI 9520091B SI 9520091 A SI9520091 A SI 9520091A SI 9520091 A SI9520091 A SI 9520091A SI 9520091 B SI9520091 B SI 9520091B
- Authority
- SI
- Slovenia
- Prior art keywords
- compound
- formula
- polymorphic form
- solvent
- suitable solvent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Reciprocating, Oscillating Or Vibrating Motors (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Claims (16)
1 EP O 776 323 Bi SI 9520091 IE-1/967 PATENTNI ZAHTEVKI 1 Spojina, značilna po tem, da ima formulo (I): CH,
: HBr (I)
2. Kristalna α-polimorfna oblika spojine po zahtevku 1, značilna po tem, da infra-rdeči spekter pokaže znatne absorpcijske pasove pri v=3371, 3293, 2713, 2524, 1419, 1343, 1307, 1264, 1151, 1086, 1020, 1008, 999, 922, 900, 805, 758, 740, 728, 689, 672, 652, 640, 598, 581, 573, 531, 498, 465, 457, 443, 428, 422, 414 in 399 cm"1.
3. Spojina po zahtevku 2, značilna po tem, da je nadalje karakterizirana z rentgenskim difrakcijskim vzorcem praška, ki smo ga dobili z uporabo bakrene radiacije filtrirane z grafitnim monokromatorjem (λ=0.15405 nm) , ki je pokazala glavne vrhove pri 9.7, 10.7, 15.9, 16.5, 17.8, 18.3, 19.3, 19.8, 20.1, 21.2, 24.4, 25.5, 25.8, 26.7, 27.6 in 29.4 stopinjah 2Θ.
4. Kristalna β-polimorfna oblika spojine po zahtevku 1, značilna po tem, da ima infra-rdeči sprekter, ki je pokazal večje absorpcijske pasove pri v=3239, 2672, 2656, 2632, 1409, 1366, 1351, 1334, 1303, 1293, 1152, 1138, 1122, 1098, 1086, 791, 771, 746, 688, 634, 557, 528, 484, 476, 469, 463, 455, 432, 424, 413 in 401 cm"1. 2 .
5. Spojina po zahtevku 4, značilna po tem, da ima vzorec rentgenske analize praška, ki smo ga opravili z uporabo bakrene radiacije filtrirane z grafitnim monokromatorjem (λ=0.15405 nm), ki kaže glavne vrhove pri 11.0, 17.2, 19.2, 20.1, 21.6, 22.6, 23.6 in 24.8 stopinj 2Θ.
6. Farmacevtski sestavek, značilen po tem, da vključuje spojino po kateremkoli izmed zahtevkov 2 in 3, skupaj z farmacevtsko aktivnim topilom ali nosilcem.
7. Farmacevtski sestavek, po zahtevku 6, značilen po tem, da je v trdni dozirni obliki.
8. Spojina po kateremkoli izmed zahtevkov 2 in 3, ali farmacevtski sestavek po kateremkoli izmed zahtevkov 6 in 7, značilen po tem, da sta uporabna kot zdravilo.
9. Uporaba spojine po kateremkoli izmed zahtevkov 2 in 3, ali farmacevtskega sestavka po kateremkoli izmed zahtevkov 6 in 7, značilna po tem, da gre za izdelavo zdravila za kurativno ali profilaktično zdravljenje zdravstvenih stanj za katerega je indiciran selektivni agonist 5-HTi receptorjev.
10. Uporaba po zahtevku 9, značilna po tem, da je zdravstveno stanje migrena ali s to boleznijo povezano stanje kakršna so pogosti glavoboli, kronična paroksimalna hemikranija, glavoboli povezani s krvožilnimi nemiri ali depresija, tesnoba, hranilne motnje, debelost, zloraba zdravil, hipertenzija ali emeza. 3
11. Postopek za pripravo kristalne α-polimorfne oblike spojine s formulo (I):
značilen po tem, da ima infra rdeči spekter, ki kaže večje absorpcijske pasove pri v=3371, 3293, 2713, 2524, 1419, 1343, 1307, 1264, 1151, 1086, 1020, 1008, 999, 922, 900, 805, 758, 740, 728, 689, 672, 652, 640, 598, 581, 573, 531, 498, 465, 457, 443, 428, 422, 414 in 399 cm-1, ter vključuje: a) obdelavo raztopine spojine po formuli (II):
v prvem ustreznem topilu z vodno raztopino vodikovega bromida, čemur sledi kristalizacija izoliranega neprečiščenega olja iz drugega ustreznega topila; b) kristalizacija β-polimorfe oblike spojine po formuli (I), karakterizirane z infra rdečim spektrom, ki kaže glavne absorpcijske vrhove pri v=3239, 2672, 2656, 2632, 1409, 1366, 1351, 1334, 1303, 1293, 1152, 1138, 1122, 1098, 1086, 791, 771, 746, 688, 634, 557, 528, 484, 476, 469, 463, 455, 432, 424, 413 in 401 cm'1, iz ustreznega topila, čemur sledi ublatenje dobljene mešanice; ali 4 c) obdelava raztopine spojine po formuli (II) v ustreznem topilu z vodno mešanico vodikovega bromida ter nadaljnje ublatenje reakcijske mešanice, čemur neobvezno sledi segrevanje do obarjanja, hlajenje ter nadaljnje ublatenje.
12. Postopek po zahtevku 11, značilen po tem, da je a) prvo ustrezno topilo aceton, drugo ustrezno topilo 2-propanol, vodna raztopina vodikovega bromida pa je 49% utežnih odstotkgv, obravnavanje pa se izvaja pri 20-25°C; b) ustrezno topilo je vodni aceton; ter c) ustrezno topilo je aceton, vodna raztopina vodikovega bromida pa je 62% utežnih odstotkov, obravnavanje tega pa se izvaja pri 0 do 5°C.
13. Postopek po enem izmed zahtevkov 11 ali 12 značilen po tem, da je α-polimorfna oblika spojine po formuli (I) nadalje karakterizirana z vzorcem rentgenske difrakcije, kjer smo uporabili bakreno radiacijo filtrirano z grafitnim monokromatorjem (λ=0.15405 nm), ki je pokazala glavne vrhove pri 9.7, 10.7, 15.9, 16.5, 17.8, 18.3, 19.3, 19.8, 20.1, 21.2, 24.4, 25.5, 25.8, 26.7, 27.6 in 29.4 stopinjah 2Θ, β-polimorfna oblika spojine po formuli (I) pa je nadalje karakterizirana z vzorcem rentgenske difrakcije ki smo jo opravili z uporabo bakrene radiacije filtrirane preko grafitnega monokromatorj a (λ=0.15405 nm), ki kaže glavne vrhove pri 11.0, 17.2, 19.2, 20.1, 21.6, 22.6, 23.6 in 24.8 stopinjah 2Θ.
14. Postopek za pripravo kristalne β-polimorfične oblike spojine po formuli (I) po zahtevku 11 ali 13, značilen po tem, da vključuje obravnavanje raztopine spojine po 5 formuli (II) v ustreznem topilu z vodno raztopino vodikovega bromide.
15. Postopek po zahtevku 14, značilen po tem, da je ustrezno topilo aceton ali etersko topilo, kakršen je tetrahidrofuran ali 1,2-dimetoksietan, vodna raztopina vodikovega bromida je 49 utežnih odstotkov, obravnavanje pa se odvija pri 0 do 10°C.
16. Postopek po zahtevku 14 ali 15, značilen po tem, da je ustrezno topilo 1,2-dimetoksietan. za Pfizer Research and Development Company, N.V./S. A. Alexandra House, Earlsfort Centre Earlsfort Terrace, DUBLIN, IRSKA
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9417310A GB9417310D0 (en) | 1994-08-27 | 1994-08-27 | Therapeutic agents |
PCT/EP1995/001914 WO1996006842A1 (en) | 1994-08-27 | 1995-05-17 | Salts of an anti-migraine indole derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
SI9520091A SI9520091A (sl) | 1998-02-28 |
SI9520091B true SI9520091B (sl) | 2004-10-31 |
Family
ID=10760474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9520091A SI9520091B (sl) | 1994-08-27 | 1995-05-17 | Soli anti-migrenskega derivata indola |
Country Status (45)
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9420529D0 (en) | 1994-10-12 | 1994-11-30 | Pfizer Ltd | Indoles |
GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
CA2292673C (en) * | 1997-07-03 | 2003-04-22 | Pfizer Inc. | Pharmaceutical compositions containing eletriptan hemisulphate |
GB9714081D0 (en) * | 1997-07-03 | 1997-09-10 | Pfizer Ltd | Pharmaceutical compositions |
GB9816556D0 (en) * | 1998-07-30 | 1998-09-30 | Pfizer Ltd | Therapy |
GB9825988D0 (en) * | 1998-11-27 | 1999-01-20 | Pfizer Ltd | Indole derivatives |
GB9922963D0 (en) * | 1999-09-28 | 1999-12-01 | Pfizer Ltd | Polymorphic salt |
GB9915231D0 (en) | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
GB9923314D0 (en) | 1999-10-01 | 1999-12-08 | Pfizer Ltd | Acylation process |
CA2324116A1 (en) * | 1999-10-25 | 2001-04-25 | Susan Beth Sobolov-Jaynes | Nk-1 receptor antagonists and eletriptan for the treatment of migraine |
US7108970B2 (en) | 2000-01-07 | 2006-09-19 | Transform Pharmaceuticals, Inc. | Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state |
US6977723B2 (en) | 2000-01-07 | 2005-12-20 | Transform Pharmaceuticals, Inc. | Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions |
GB0008563D0 (en) | 2000-04-07 | 2000-05-24 | Cambridge Discovery Chemistry | Investigating different physical and/or chemical forms of materials |
GB0018968D0 (en) * | 2000-08-02 | 2000-09-20 | Pfizer Ltd | Particulate composition |
US20030166704A1 (en) * | 2000-12-20 | 2003-09-04 | Pfizer Inc. | New process |
US6579898B2 (en) | 2001-03-01 | 2003-06-17 | Pfizer Inc. | Compositions having improved bioavailability |
MXPA05010070A (es) | 2003-04-11 | 2005-11-23 | Pfizer | Combinacion farmaceutica. |
US7132549B2 (en) | 2003-05-30 | 2006-11-07 | Pfizer Inc. | Process |
GB0312478D0 (en) * | 2003-05-30 | 2003-07-09 | Pfizer Ltd | Improved process |
US6927296B2 (en) | 2003-07-23 | 2005-08-09 | Pfizer Inc. | Process |
GB0317229D0 (en) * | 2003-07-23 | 2003-08-27 | Pfizer Ltd | Improved process |
WO2007002597A2 (en) * | 2005-06-27 | 2007-01-04 | Biovail Laboratories International S.R.L. | Modified-release formulations of a bupropion salt |
EP2081893B1 (en) * | 2006-10-19 | 2011-03-23 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
US20080139510A1 (en) * | 2006-12-07 | 2008-06-12 | Abe Rose | Treatment of migraine headaches with sublingual amino acids |
EP1956018A1 (de) * | 2007-02-06 | 2008-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Herstellung eines Benzimidazolderivats |
EP2093224A1 (en) * | 2007-05-01 | 2009-08-26 | Plus Chemicals B.V. | Process for preparing eletriptan hydrobromide form beta |
US20080319205A1 (en) * | 2007-05-29 | 2008-12-25 | Roman Bednar | Process for preparing 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole |
US20100285075A1 (en) * | 2007-12-17 | 2010-11-11 | Actavis Group Ptc Ehf | Novel Hemioxalate Salt of Eletriptan |
US20090299077A1 (en) * | 2008-05-22 | 2009-12-03 | Vinod Kumar Kansal | Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan |
US8349900B2 (en) | 2008-08-07 | 2013-01-08 | Valeant International Bermuda | Bupropion hydrobromide polymorphs |
US20120027816A1 (en) * | 2009-02-25 | 2012-02-02 | Actavis Group Ptc Ehf | Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity |
WO2010116386A2 (en) * | 2009-04-08 | 2010-10-14 | Biophore India Pharmaceuticals Pvt. Ltd. | Novel polymorph of eletriptan hydrobromide and process for the preparation thereof |
IT1393700B1 (it) | 2009-04-22 | 2012-05-08 | F S I Fabbrica Italiana Sint | Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo |
WO2011004391A2 (en) * | 2009-06-25 | 2011-01-13 | Matrix Laboratories Ltd | An improved process for the preparation of eletriptan and its salt thereof |
US8754239B2 (en) | 2010-01-19 | 2014-06-17 | Sms Pharmaceuticals Limited | Process for preparing eletriptan hydrobromide having α-form |
WO2014063752A1 (en) | 2012-10-26 | 2014-05-01 | Synthon Bv | Process for making crystalline form alpha of eletriptan hydrobromide |
JP2019502761A (ja) | 2016-01-21 | 2019-01-31 | ラボラトリオス レヴィ エセエレ | ((r)−3−[(−1−メチルピロリジン−2−イル)メチル]−5−(2−フェニルスルホニルエチル)−1h−インドールを作製する方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2773875A (en) * | 1952-03-28 | 1956-12-11 | Hoffmann La Roche | Indole derivatives and method for producing same |
GB886684A (en) * | 1957-09-17 | 1962-01-10 | Upjohn Co | Improvements in or relating to heterocyclic compounds and the manufacture thereof |
GB851780A (en) * | 1958-02-25 | 1960-10-19 | Rhone Poulenc Sa | New indole derivatives |
US3037031A (en) * | 1959-08-04 | 1962-05-29 | Warner Lambert Pharmaceutical | Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor |
GB893707A (en) * | 1960-03-01 | 1962-04-11 | Roche Products Ltd | Novel tryptamine derivatives and a process for the manufacture thereof |
GB966562A (en) * | 1961-04-06 | 1964-08-12 | Parke Davis & Co | Amine compounds and means of producing the same |
US4092315A (en) * | 1976-03-01 | 1978-05-30 | Pfizer Inc. | Novel crystalline forms of prazosin hydrochloride |
ZA795239B (en) * | 1978-10-12 | 1980-11-26 | Glaxo Group Ltd | Heterocyclic compounds |
ZW19381A1 (en) * | 1980-08-12 | 1983-03-09 | Glaxo Group Ltd | Heterocyclic compounds |
US4803218A (en) * | 1982-09-29 | 1989-02-07 | Mcneilab, Inc. | 3-aminoalkyl-1H-indole-5-urea and amide derivatives |
GB8600397D0 (en) * | 1986-01-08 | 1986-02-12 | Glaxo Group Ltd | Chemical compounds |
DK158590D0 (da) * | 1990-07-02 | 1990-07-02 | Lundbeck & Co As H | Indolderivater |
US5559129A (en) * | 1990-10-15 | 1996-09-24 | Pfizer Inc | Indole derivatives |
US5578612A (en) * | 1990-10-15 | 1996-11-26 | Pfizer Inc. | Indole derivatives |
US5559246A (en) * | 1990-10-15 | 1996-09-24 | Pfizer Inc. | Indole derivatives |
US5545644A (en) * | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
CA2091562C (en) * | 1990-10-15 | 2001-03-27 | John Eugene Macor | Indole derivatives useful in psychotherapeutics |
US5208248A (en) * | 1991-01-11 | 1993-05-04 | Merck Sharpe & Dohme, Ltd. | Indazole-substituted five-membered heteroaromatic compounds |
CZ283018B6 (cs) * | 1991-02-01 | 1997-12-17 | Merck Sharp And Dohme Limited | Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi |
WO1993011106A1 (en) * | 1991-11-25 | 1993-06-10 | Pfizer, Inc. | Indole derivatives |
GB9201038D0 (en) * | 1992-01-16 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
US5409941A (en) * | 1992-02-03 | 1995-04-25 | Pfizer Inc. | 5-heteroyl indole derivatives |
TW288010B (sl) * | 1992-03-05 | 1996-10-11 | Pfizer | |
CZ281763B6 (cs) * | 1992-04-07 | 1997-01-15 | Pfizer Inc. | Indolové deriváty představující 5-HT1 agonisty, způsob jejich přípravy, farmaceutické prostředky obsahující tyto látky, jejich použití a meziprodukty postupu přípravy |
ATE148465T1 (de) * | 1992-04-10 | 1997-02-15 | Pfizer | Acylaminoindolderivate als 5-ht1 agonisten |
GB9207930D0 (en) * | 1992-04-10 | 1992-05-27 | Pfizer Ltd | Indoles |
GB9208161D0 (en) * | 1992-04-14 | 1992-05-27 | Pfizer Ltd | Indoles |
GB9210400D0 (en) * | 1992-05-15 | 1992-07-01 | Merck Sharp & Dohme | Therapeutic agents |
FR2701026B1 (fr) * | 1993-02-02 | 1995-03-31 | Adir | Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
EP0695301B1 (en) * | 1993-04-22 | 1996-10-30 | Pfizer Limited | Indole derivatives as 5-ht1-like agonists for use in migraine |
AP486A (en) * | 1993-04-27 | 1996-04-16 | Pfizer | Indole derivatives. |
CZ59996A3 (en) * | 1993-08-31 | 1996-06-12 | Pfizer | 5-arylindole derivatives per se and for treating diseases, intermediates for their preparation and pharmaceutical compositions based thereon |
-
1994
- 1994-08-27 GB GB9417310A patent/GB9417310D0/en active Pending
-
1995
- 1995-05-17 AU AU27352/95A patent/AU691005B2/en not_active Expired
- 1995-05-17 PL PL95318319A patent/PL180867B1/pl unknown
- 1995-05-17 KR KR1019970701281A patent/KR100228952B1/ko not_active IP Right Cessation
- 1995-05-17 WO PCT/EP1995/001914 patent/WO1996006842A1/en active IP Right Grant
- 1995-05-17 JP JP8508431A patent/JP2904588B2/ja not_active Expired - Lifetime
- 1995-05-17 RO RO97-00375A patent/RO116400B1/ro unknown
- 1995-05-17 DK DK95922465.0T patent/DK0776323T3/da active
- 1995-05-17 RU RU97104885/04A patent/RU2159241C2/ru active
- 1995-05-17 MX MX9701538A patent/MX9701538A/es active IP Right Grant
- 1995-05-17 US US08/776,680 patent/US6110940A/en not_active Expired - Lifetime
- 1995-05-17 CZ CZ1997563A patent/CZ287693B6/cs not_active IP Right Cessation
- 1995-05-17 DE DE69501620T patent/DE69501620T2/de not_active Expired - Lifetime
- 1995-05-17 SK SK248-97A patent/SK282922B6/sk not_active IP Right Cessation
- 1995-05-17 UA UA97031432A patent/UA45980C2/uk unknown
- 1995-05-17 CA CA002198599A patent/CA2198599C/en not_active Expired - Lifetime
- 1995-05-17 AT AT95922465T patent/ATE163182T1/de active
- 1995-05-17 NZ NZ288210A patent/NZ288210A/en not_active IP Right Cessation
- 1995-05-17 HU HU9701704A patent/HU227822B1/hu unknown
- 1995-05-17 SI SI9520091A patent/SI9520091B/sl unknown
- 1995-05-17 ES ES95922465T patent/ES2112650T3/es not_active Expired - Lifetime
- 1995-05-17 CN CN95194697A patent/CN1066727C/zh not_active Expired - Lifetime
- 1995-05-17 EP EP95922465A patent/EP0776323B1/en not_active Expired - Lifetime
- 1995-07-27 AP APAP/P/1995/000754A patent/AP576A/en active
- 1995-08-14 SA SA95160156A patent/SA95160156B1/ar unknown
- 1995-08-16 TN TNTNSN95092A patent/TNSN95092A1/fr unknown
- 1995-08-21 MA MA23992A patent/MA23650A1/fr unknown
- 1995-08-21 IL IL11501395A patent/IL115013A/xx not_active IP Right Cessation
- 1995-08-23 DZ DZ950104A patent/DZ1923A1/fr active
- 1995-08-23 PE PE1995277098A patent/PE41596A1/es not_active IP Right Cessation
- 1995-08-23 CO CO95037815A patent/CO4410334A1/es unknown
- 1995-08-25 HR HR9417310.1A patent/HRP950460B1/xx not_active IP Right Cessation
- 1995-08-25 BR BRPI9503812A patent/BRPI9503812B1/pt not_active IP Right Cessation
- 1995-08-25 MY MYPI95002536A patent/MY113733A/en unknown
- 1995-08-25 YU YU56995A patent/YU49287B/sh unknown
- 1995-08-25 TR TR95/01061A patent/TR199501061A2/xx unknown
- 1995-08-25 ZA ZA9507142A patent/ZA957142B/xx unknown
- 1995-08-26 EG EG71195A patent/EG23822A/xx active
-
1996
- 1996-12-19 IS IS4401A patent/IS1850B/is unknown
-
1997
- 1997-02-20 BG BG101250A patent/BG61840B1/bg unknown
- 1997-02-26 LV LVP-97-34A patent/LV11800B/en unknown
- 1997-02-26 NO NO19970861A patent/NO311297B1/no not_active IP Right Cessation
- 1997-02-26 FI FI970800A patent/FI113768B/fi not_active IP Right Cessation
- 1997-02-27 OA OA60969A patent/OA10600A/en unknown
-
1998
- 1998-03-27 GR GR980400660T patent/GR3026475T3/el unknown
-
2000
- 2000-06-15 US US09/596,017 patent/US6380226B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI9520091B (sl) | Soli anti-migrenskega derivata indola | |
DE60218037T2 (de) | Neue indolderivate mit affinität zum 5-ht6-rezeptor | |
Martín et al. | Synthesis and conformational study of acridine derivatives related to 1, 4‐dihydropyridines | |
AU2016240841C1 (en) | Crystal of 3,5-disubstituted benzene alkynyl compound | |
IE58416B1 (en) | Polycyclic aromatic compounds | |
RU97104885A (ru) | Соли производного индола против мигрени | |
JPS61191683A (ja) | 新規な酸性インド−ル化合物 | |
JPH0216315B2 (sl) | ||
PT2262505E (pt) | Sólidos de gama-carbolinas fusionadas a heterociclos substituídos | |
PT88669B (pt) | Processo para a preparacao de compostos aromaticos e hetero-aromaticos alfa,alfa-di-substituidos utilizados para aumentar a percepcao | |
JP6768674B2 (ja) | 新規ベンズイミダゾール化合物およびその医薬用途 | |
Lahari et al. | Design and synthesis of novel isatin derivatives as potent analgesic, anti-inflammatory and antimicrobial agents | |
Dişli et al. | Synthesis and antimicrobial activity of new pyrimidine derivatives incorporating 1H‐Tetrazol‐5‐ylthio moiety | |
IE58102B1 (en) | Active compounds | |
PT70921B (de) | Neue indolderivate deren herstellung und deren verwendung als arzneimittel | |
Sturm et al. | (H+-K+)-ATPase inhibiting 2-[(2-pyridylmethyl) sulfinyl] benzimidazoles. 1. Their reaction with thiols under acidic conditions. Disulfide containing 2-pyridiniobenzimidazolides as mimics for the inhibited enzyme | |
GB2185977A (en) | A benzohcinnoline compoun | |
WO2000078729A1 (en) | Crystalline forms of lansoprazole | |
EA003941B1 (ru) | 2-аминопиридины, содержащие конденсированные кольца в качестве заместителей | |
CA2464306A1 (en) | Olanzapine dihydrate-ii a process for its preparation and use thereof | |
KR900008814B1 (ko) | 살균성 폴리시클릭 화합물의 제조방법 | |
Liang et al. | A facile synthesis and herbicidal activities of novel fluorine-containing thiazolo [4, 5-d] pyrimidin-7 (6H)-ones | |
KR101589910B1 (ko) | 결정형 α 탈티레린의 제조방법 및 결정형의 변환방법 | |
SK283188B6 (sk) | Spôsob prípravy kryštalickej formy 3/2 hydrátu 7-[(7-(S)- amino-5-azaspiro[2.4]-heptan-5-yl]-8-chlór-6-flór-1-[(1R,2S)-2- flórcyklopropyl]-4-oxo-1,4-dihydrochinolín-3-karboxylovej kyseliny | |
MX9706339A (es) | Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
IF | Valid on the event date | ||
SP73 | Change of data on owner |
Owner name: PFIZER IRELAND PHARMACEUTICALS; IE Effective date: 20050406 |
|
SP73 | Change of data on owner |
Owner name: PFIZER IRELAND PHARMACEUTICALS; IE Effective date: 20110826 |